Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Lonza Group AG

Campus Biotech is an interdisciplinary center dedicated to neuroscience and digital and global health. It aims to transform innovation into medical advancements.

Campus Biotech

Applikon Bio provides bioprocess equipment and automation solutions for biotechnology research and production

Applikon Bio

Fertypharm develops a portfolio of exclusive and innovative products that provide added value over other market alternatives. The company focuses on fertility and offers dietary supplements with specific probiotics for fertility and pregnancy.

Metric
Company Name	Lonza Group AG	Campus Biotech	Applikon Bio	Fertypharm
Symbol	LONN
MSH ID	COM:LONZA	CH:CAMPUSBIOTECH	COM:APPLIKONBIO	COM:FERTYPHARM
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector		Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry		Life Sciences	Biotechnology Equipment	Pharmaceutical
Country	CH	CH	NL	ES
Stage
Employee Count	17.90K
Website	lonza.com	campusbiotech.ch	applikonbio.com	fertypharm.com
LinkedIn		campus-biotech	applikon-biotechnology
Founders

Metric
Market Cap	31.42B
Enterprise Value
Monthly Web Traffic		6.83K
Web Traffic Growth		-0.59
Valuation
Raised Capital

Metric
Revenue	7.66B
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.59B
EBITDA	2.26B
Operating Income	1.55B
Net Income	745.51M
EPS	10.12
Diluted EPS	10.12
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.32
Operating Profit Margin	0.21
EBITDA Margin	0.29
Net Profit Margin	0.14
Return on Equity	0.14
Return on Assets	0.08
Return on Capital Employed	0.13

COM:LONZA

Lonza Group AG

Last Close

521.40

25/11 09:22

Market Cap

31.42B

Beta: -

Volume Today

11.16K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	27.14
P/B Ratio	3.11
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.29
EV Multiple	20.30

Metric
Days Sales Outstanding
Days Payables Outstanding	46.00
Days Inventory Outstanding	131.99
Operating Cycle	218.98
Cash Conversion Cycle	218.98
Asset Turnover	0.59

Metric
Operating Cash Flow	1.61B
Free Cash Flow	-338.56M
Cash Flow to Debt	0.76
Operating Cash Flow/Sales	0.23
Free Cash Flow Yield	-0.03

Metric
Cash & Equivalents	1.67B
Accounts Receivable
Inventory	1.81B
Goodwill	3.14B
Debt to Capitalization	0.29
Debt to Assets	0.15
Current Ratio	1.86
Quick Ratio	1.38

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue	0.02
SG&A to Revenue	0.12